Taro recalls skin treatment cream from US, Puerto Rico markets

Taro Pharmaceuticals, the Israel -based subsidiary of Sun Pharmaceuticals, has recalled nearly 40,000 tubes of Fluorouracil topical cream, used to treat various skin conditions, from the American market.

Taro Pharmaceuticals USA Inc has voluntarily recalled 39,982 tubes of Fluorouracil Topical Cream USP from the US and Puerto Rico markets, US Food and Drug Administration (USFDA) said in its enforcement report.

The reason for the class II recall is that 'product lacks stability', it added.

As per the USFDA, class II recalls are done in a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Sun Pharma had acquired a controlling stake in Taro in September, 2010. The Mumbai-based firm currently holds 66.5 per cent stake in Taro.

Topical fluorouracil is used to treat certain skin conditions in which cells are multiplying rapidly. It is used to treat cancerous or precancerous conditions including solar keratoses, actinic keratosis and superficial basal cell carcinoma.

ALSO READ

Part rock concert, part investment workshop: Warren Buffett leads annual meeting like no other

Carmakers' rumbles against quadricycle grow louder

Mukesh Ambani in race to buy IMG Worldwide

Enter the compact luxury